Sign In
Buy ZNTL
$4.74
-0.180 (-3.66%)
At Close: Jul 31, 2026
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06:00pm, Friday, 01'st Mar 2024
NEW YORK & SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiate
Wall Street Analysts Think Zentalis Pharmaceuticals, Inc. (ZNTL) Could Surge 136.44%: Read This Before Placing a Bet
10:56am, Wednesday, 28'th Feb 2024
The consensus price target hints at a 136.4% upside potential for Zentalis Pharmaceuticals, Inc. (ZNTL). While empirical research shows that this sought-after metric is hardly effective, an upward tre
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
07:00am, Wednesday, 28'th Feb 2024
NEW YORK and SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiat
Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates
07:00am, Tuesday, 27'th Feb 2024
Robust azenosertib clinical development plan ongoing and on track with multiple clinical catalysts anticipated, including monotherapy and combination data readouts in gynecological and other cancer ty
Down -19.06% in 4 Weeks, Here's Why You Should You Buy the Dip in Zentalis Pharmaceuticals, Inc. (ZNTL)
10:37am, Wednesday, 14'th Feb 2024
Zentalis Pharmaceuticals, Inc. (ZNTL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street
Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare Life Sciences Conference
07:00am, Tuesday, 13'th Feb 2024
NEW YORK and SAN DIEGO, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiat
What Makes Zentalis Pharmaceuticals, Inc. (ZNTL) a New Buy Stock
01:01pm, Thursday, 08'th Feb 2024
Zentalis Pharmaceuticals, Inc. (ZNTL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term
Zentalis Pharmaceuticals: Azenosertib Continues To Impress
02:32am, Wednesday, 07'th Feb 2024
Zentalis Pharmaceuticals is positioned to become an oncology leader with its lead drug candidate, azenosertib, showing promising results in difficult-to-treat cancers. The company's financial health i
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:00pm, Thursday, 01'st Feb 2024
NEW YORK and SAN DIEGO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiat
Zentalis Pharmaceuticals Strengthens Management Team with Key Appointments
07:00am, Thursday, 25'th Jan 2024
Diana Hausman, M.D., Accomplished Oncologist and Drug Developer, Appointed Chief Medical Officer Kyle Rasbach, Ph.D.
LOS ANGELES, CA / ACCESSWIRE / January 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zentalis Pharma
Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform
07:00am, Monday, 08'th Jan 2024
BOTHELL, Wash. & SAN DIEGO & NEW YORK--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM) and Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), today announced that they have entered into an exclusive, wor
LOS ANGELES, CA / ACCESSWIRE / January 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zentalis Pharma
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:49pm, Tuesday, 02'nd Jan 2024
NEW YORK and SAN DIEGO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiat
Zentalis: Latest Market Sell-Off Looks Justified With Data Catalysts Long Way Off
10:35am, Tuesday, 14'th Nov 2023
Zentalis is a biotech company focused on developing Azenosertib, a Wee1 inhibitor, for ovarian cancer. The company has faced stock sell-offs due to mixed data from clinical trials of Azenosertib in co
